SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 13.54M
March 31, 2026 13.06M
December 31, 2025 11.91M
September 30, 2025 12.30M
June 30, 2025 12.11M
March 31, 2025 11.78M
December 31, 2024 11.78M
September 30, 2024 11.66M
June 30, 2024 12.12M
March 31, 2024 12.86M
December 31, 2023 13.64M
September 30, 2023 13.70M
June 30, 2023 14.03M
March 31, 2023 13.57M
December 31, 2022 15.31M
September 30, 2022 15.93M
June 30, 2022 15.24M
March 31, 2022 14.91M
December 31, 2021 12.00M
September 30, 2021 11.18M
June 30, 2021 11.03M
March 31, 2021 10.57M
December 31, 2020 10.30M
September 30, 2020 10.24M
June 30, 2020 9.817M
Date Value
March 31, 2020 9.854M
December 31, 2019 9.623M
September 30, 2019 9.04M
June 30, 2019 9.48M
March 31, 2019 9.371M
December 31, 2018 9.452M
September 30, 2018 9.874M
June 30, 2018 9.584M
March 31, 2018 8.003M
December 31, 2017 6.487M
September 30, 2017 4.872M
June 30, 2017 2.828M
March 31, 2017 2.599M
December 31, 2016 3.641M
September 30, 2016 2.749M
June 30, 2016 5.355M
March 31, 2016 9.88M
December 31, 2015 13.23M
September 30, 2015 20.94M
June 30, 2015 23.42M
March 31, 2015 23.91M
December 31, 2014 24.15M
September 30, 2014 21.69M
June 30, 2014 23.74M
March 31, 2014 23.59M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
NeoGenomics, Inc. 359.09M
Quest Diagnostics, Inc. 2.038B
Labcorp Holdings, Inc. 2.219B
OPKO Health, Inc. 205.85M
Psychemedics Corp. --